Shinichi Hasako

Shinichi Hasako is a Manager at Taiho Pharmaceutical Co., Ltd., a pharmaceutical company based in Tokyo, Japan, where he oversees discovery and preclinical research initiatives focused on oncology drug development. He holds a PhD in Oncology and Cancer Biology from the University of Tsukuba, alongside an MPhil in Cell and Molecular Biology and a BPharm from Hiroshima University. In his current corporate capacity, Hasako maintains a primary professional focus on advancing targeted oncological therapeutics from initial laboratory discovery through the rigorous preclinical evaluation phases. His scientific research specifically targets cancer drug discovery, evidenced by his role as the corresponding author on a notable 2018 publication in the journal Molecular Cancer Therapeutics. This specific study detailed the preclinical development of TAS6417, a novel EGFR inhibitor designed to specifically target exon 20 insertion mutations to advance oncology pharmaceuticals.